B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment

Andreou, Nikolaos-Panagiotis; Legaki, Evangelia; Dovrolis, Nikolas; Boyanov, Nikola; Γεωργίου, Κωνσταντίνος; Gkouskou, Kalliopi; Gazouli, Maria

doi:10.1016/j.dld.2020.11.030

Cited by 15 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BAFF is mainly expressed in innate immune cells such as monocytes, dendritic cells, macrophages, and neutrophils [163]. Responders to IFX treatment had higher BAFF levels at baseline compared to non-responders [164].…”

Section: Novel Biomarkersmentioning

confidence: 99%

Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Wagatsuma

Yokoyama

Nakase

2021

Life

View full text Add to dashboard Cite

The number of patients with inflammatory bowel disease (IBD) is increasing worldwide. Endoscopy is the gold standard to assess the condition of IBD. The problem with this procedure is that the burden and cost on the patient are high. Therefore, the identification of a reliable biomarker to replace endoscopy is desired. Biomarkers are used in various situations such as diagnosis of IBD, evaluation of disease activity, prediction of therapeutic effect, and prediction of relapse. C-reactive protein and fecal calprotectin have a lot of evidence as objective biomarkers of disease activity in IBD. The usefulness of the fecal immunochemical test, serum leucine-rich glycoprotein, and urinary prostaglandin E major metabolite have also been reported. Herein, we comprehensively review the usefulness and limitations of biomarkers that can be used in daily clinical practice regarding IBD. To date, no biomarker is sufficiently accurate to replace endoscopy; however, it is important to understand the characteristics of each biomarker and use the appropriate biomarker at the right time in daily clinical practice.

show abstract

Section: Novel Biomarkersmentioning

confidence: 99%

Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Wagatsuma

Yokoyama

Nakase

2021

Life

View full text Add to dashboard Cite

show abstract

“…Of note, in a recent study, Andreou et al explored whether serum BAFF can serve as a potential prognostic indicator of therapeutic response to Infliximab treatment in CD [ 117 ]. Baseline serum BAFF values were significantly higher in the responders’ group in comparison to non-responders to infliximab (610.03 ± 167.55 pg/mL vs. 267.09 ± 107 pg/mL), with both groups having higher serum levels than healthy controls (128.16 ± 70.10 pg/mL).…”

Section: Baff In Ibdmentioning

confidence: 99%

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

et al. 2021

View full text Add to dashboard Cite

As early commencement of inflammatory bowel disease (IBD) treatment has been shown to substantially improve outcomes, it is of utmost importance to make a timely diagnosis of this disease. Despite undisputed sensitivity of fecal calprotectin, the most widely accepted IBD biomarker, in discriminating between irritable bowel syndrome (IBS) and IBD, as well as recognized role in monitoring disease activity and response to therapy, perhaps the biggest setback of calprotectin use in IBD is lack of specificity. Therefore, an additional biomarker in IBD is warranted. B-cell activating factor (BAFF), a member of the tumor necrosis factor (TNF) superfamily, recently emerged as a viable candidate for this role. So far, overproduction of BAFF has been observed in various autoimmune diseases, most notably in systemic lupus erythematosus, where BAFF-inhibitor belimumab was approved for treatment. As BAFF levels were also shown to correlate with indices of IBD, in this review we aimed to summarize the current evidence with respect to the role of BAFF in diagnosis and assessing the activity of IBD, as well as putative therapeutic implications that may arise from exploring of this relation.

show abstract

“…37 Another study reported high serum BAFF concentrations in patients with Crohn's disease responding to infliximab treatment compared with controls and non-responders, and this was reduced after treatment. 38 Also, in spondyloarthropathy, infliximab treatment increased circulating memory B cells. 39 In this context, we think our findings of a tendency to increased percentage of PB B cells and a significant negative correlation between PB and BALF B cells after, but not before treatment, may indicate that a disturbed B cell homeostasis, including dysregulated BAFF, is restored from infliximab.…”

Section: Open Accessmentioning

confidence: 99%

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis

et al. 2021

View full text Add to dashboard Cite

BackgroundTumour necrosis factor α (TNF-α) is pivotal in sarcoid granuloma formation, and inhibitors of TNF-α offer an attractive third-line treatment option in sarcoidosis. The sarcoid inflammation is characterised by an exaggerated T helper 1 response, and evidence indicates a contribution of dysregulated and/or deficient NK (natural killer) cells, CD56+ T cells and B cells.ObjectivesInsight into how TNF-α inhibitors influence these cells may provide more information on inflammatory mechanisms in sarcoidosis and improve understanding of such treatment. We therefore evaluated treatment effects of the TNF-α inhibitor infliximab on lung and peripheral blood (PB) NK, CD56+ T cells and B cells.MethodsFifteen patients were assessed with PB samples, spirometry and CT scan, and 11 of them also underwent bronchoalveolar lavage (BAL) close to start of infliximab treatment. These investigations were repeated after 6 months of treatment.ResultsTwelve out of 15 patients disclosed a clinical improvement at follow-up. Median percentage of BAL fluid (BALF) CD56+ T cells increased while a decrease was seen in PB (p<0.05 and 0.005, respectively). No significant changes were observed for NK cells. There was a trend towards increased median percentage of PB B cells (p=0.07), and a negative correlation was observed between PB and BALF B cells after treatment (p<0.05).ConclusionIn conclusion, 6 months of infliximab treatment in patients with sarcoidosis, of whom the majority benefited from the treatment, influenced immune cells in the lung and circulation differently, highlighting the importance of investigating several compartments concomitantly when evaluating treatment effects on the inflammatory activity.

show abstract

B-cell activating factor (BAFF) expression is associated with Crohn's disease and can serve as a potential prognostic indicator of disease response to Infliximab treatment

Cited by 15 publications

References 45 publications

Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease

Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis

Contact Info

Product

Resources

About